ClinicalTrials.gg
CompletedNCT03122353Updated Mar 7, 2018

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

A Phase 1 interventional study of Calcipotriene and betamethasone suspension and Taclonex in Scalp Psoriasis, sponsored by Tolmar Inc.. Completed at 34 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-07.

Sponsored by Tolmar Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2017, 9 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
699
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
10th of 47
699 · median 200
Started
2017
with 4 others
Phase 1
5 of 47
none open now
Registered
32nd of 47
by date

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 10th largest by enrollment, is one of 5 that started in 2017, is one of 5 in phase 1, and was the 32nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

This study will be conducted to evaluate the therapeutic bioequivalence of a TEST formulation of calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064% to the RLD.

Read the detailed description

Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Parallel Design, Bioequivalence with Clinical Endpoints.

03

Conditions studied

  • Scalp Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or non-pregnant, non-lactating female, at least 18 years of age.
  • Female subjects of (excluding women who are or premenarchal, surgically sterilized or for at least 2 years).
  • A clinical diagnosis of stable (at least 6 months) scalp psoriasis involving at least 10% of the scalp and clinical signs of psoriasis vulgaris on trunk and/or limbs.
  • Scalp psoriasis consistent with at least moderate disease severity (grade ≥ 3) using the Physician's Global Assessment (PGA) of disease severity.
  • Plaque elevation of at least moderate severity (grade ≥ 3) at the scalp target lesion site using the Psoriasis Area Severity Index (PASI). The most severe lesion at Baseline will be identified as the scalp target lesion.
  • Agree to stop use of all other topical or systemic antipsoriatic treatments, , drugs, calcium supplements and Vitamin D supplements or Vitamin D analogs at a dose > 400 IU/day during the study.
  • Currently in general good health and free from any disease, other than scalp psoriasis and psoriasis vulgaris, that may interfere with the study evaluations.
  • Willing and able to understand and comply with the requirements of the study, apply IP as instructed, attend required study visits, comply with study prohibitions, and be able to complete the study.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis.
  • Other inflammatory skin disease in the scalp that may confound the evaluation of the scalp psoriasis (eg, atopic dermatitis, contact dermatitis, tinea capitis).
  • History of to any component of TEST or RLD.
  • Current or past history of hypercalcemia, hypercalciuria, vitamin D toxicity, severe renal insufficiency, or hepatic disorders.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
699 participants (actual)

Study arms

  • Experimental
    Calcipotriene Hydrate and Betamethasone

    Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%

    Drug: Calcipotriene and betamethasone suspension

  • Active comparator
    Taclonex

    Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%

    Drug: Taclonex

  • Placebo comparator
    Placebo

    Topical suspension without active ingredient

    Drug: Placebo

Interventions

  • DrugCalcipotriene and betamethasone suspension

    Drug pages: Calcipotriene · Betamethasone

    Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%

    Also known as: Calcipotriene, betamethasone

  • DrugTaclonex

    Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%

    Also known as: Calcipotriene, betamethasone

  • DrugPlacebo

    vehicle used as placebo

    Also known as: Vehicle

06

What researchers measure

Primary outcomes

  1. Psoriasis Area Severity Index (PASI)

    To evaluate the change in clinical outcome of patients exposed to Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%, Taclonex and Vehicle for scalp psoriasis. From baseline to end of study.

    Time frame: at Day 1, Day 28

  2. Physician Global Assessment (PGA)

    To evaluate the change in global severity of skin of patients exposed to Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%, Taclonex, and Vehicle for scalp psoriasis. From baseline to end of study.

    Time frame: at Day 1, Day 28

  3. Body Surface Area (BSA)

    To evaluate the total body area of skin affected by psoriasis.

    Time frame: at Day 1

  4. Adverse Events and Serious Adverse Events

    Risk for adverse events and serious adverse events for exposed to Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%, Taclonex and Vehicle for scalp psoriasis

    Time frame: at Day 28

07

Study locations

34 sites
  • Site 17
    Hot Springs, Arkansas 71913, United States
  • Site 29
    Fremont, California 94538, United States
  • Site 12
    Los Angeles, California 90036, United States
  • Site 18
    Sherman Oaks, California 91403, United States
  • Site 34
    Denver, Colorado 80220, United States
  • Site 20
    Boca Raton, Florida 33486, United States
  • Site 01
    Brandon, Florida 33511, United States
  • Site 25
    Coral Gables, Florida 33134, United States
  • Site 11
    Hialeah, Florida 33012, United States
  • Site 26
    Miami, Florida 33126, United States
  • Site 04
    Miami, Florida 33175, United States
  • Site 05
    Miramar, Florida 33027, United States
  • Site 02
    Tampa, Florida 33609, United States
  • Site 03
    Tampa, Florida 33618, United States
  • Site 23
    Winter Park, Florida 32792, United States
  • Site 16
    Plainfield, Indiana 46168, United States
  • Site 19
    Olathe, Kansas 66061, United States
  • Site 33
    Lake Charles, Louisiana 70601, United States
  • Site 27
    Saint Joseph, Missouri 64506, United States
  • Site 14
    Las Vegas, Nevada 89106, United States
  • Site 09
    High Point, North Carolina 27262, United States
  • Site 28
    Hazleton, Pennsylvania 18201, United States
  • Site 24
    Upper Saint Clair, Pennsylvania 15241, United States
  • Site 32
    Johnston, Rhode Island 02919, United States
  • Site 07
    Anderson, South Carolina 29621, United States
  • Site 35
    Mount Pleasant, South Carolina 29464, United States
  • Site 21
    Austin, Texas 78759, United States
  • Site 06
    Dallas, Texas 75234, United States
  • Site 30
    El Paso, Texas 79902, United States
  • Site 08
    Murphy, Texas 75094, United States
  • Site 15
    San Antonio, Texas 78229, United States
  • Site 31
    San Antonio, Texas 78229, United States
  • Site 10
    Salt Lake City, Utah 84117, United States
  • Site 22
    Norfolk, Virginia 23507, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Nov 2017, 7 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 7 months is below that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2017
First posted
Apr 20, 2017
StartActual
Apr 11, 2017
Primary completionActual
Nov 15, 2017
CompletionActual
Nov 15, 2017
Last update
Mar 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03122353
Lead sponsor
Tolmar Inc.
Responsible party
Sponsor
First posted
Apr 20, 2017
Start date
Apr 11, 2017
Primary completion
Nov 15, 2017
Completion
Nov 15, 2017
Last update
Mar 7, 2018

Study contacts

Jim Joffrion
study director · Catawba Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Betamethasone

Start the discussion